 AUSTIN, Texas., Dec. 01, 2020 GLOBE NEWSWIRE -- Plus Therapeutics, Inc. Nasdaq: PSTV the Company, a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECTTM Phase 1 clinical trial, currently supported by the National Cancer Institute NCI. ReSPECT is a multi-center, dose-finding study evaluating the Companys lead investigational asset, Rhenium NanoLiposome RNLTM, in patients with recurrent glioblastoma GBM. 